Introduction
Burkitt’s lymphoma is a rare and aggressive form of non-Hodgkin lymphoma, a cancer of the lymphatic system. It is named after Denis Burkitt, a British surgeon who first described the disease in African children in the 1950s. This lymphoma is characterized by the rapid growth of tumors in the lymph nodes, bone marrow, and various organs. There are three main types of Burkitt’s lymphoma: endemic, sporadic, and immunodeficiency-associated. Each type has distinct epidemiological and clinical features, but all share similar molecular characteristics and require prompt treatment due to their rapid progression.
Types of Burkitt’s Lymphoma
- Endemic Burkitt’s Lymphoma: This type is most common in equatorial Africa and Papua New Guinea. It predominantly affects children aged 4 to 7 years. Endemic Burkitt’s lymphoma is strongly associated with the Epstein-Barr virus (EBV), which is present in nearly all cases. The disease often presents with tumors in the jaw or facial bones, but it can also affect the gastrointestinal tract, kidneys, ovaries, and other organs.
- Sporadic Burkitt’s Lymphoma: Sporadic cases are found worldwide but are more common in Western countries. This type affects both children and adults and is not as closely linked to EBV as the endemic type (with EBV found in about 20-30% of cases). Sporadic Burkitt’s lymphoma often presents with abdominal tumors, which can cause symptoms such as pain, swelling, or bowel obstruction. It can also involve the central nervous system, bone marrow, and other sites.
- Immunodeficiency-Associated Burkitt’s Lympho.: This form occurs in individuals with weakened immune systems, such as those with HIV/AIDS or those who have undergone organ transplantation and are on immunosuppressive therapy. EBV is found in approximately 30-40% of these cases. This type of Burkitt’s lymphoma can present in various ways, depending on the patient’s immune status and the disease’s extent.
Pathophysiology
Burkitt’s lymphoma is characterized by the translocation of the MYC gene on chromosome 8. The most common translocation is t(8;14)(q24;q32), which brings the MYC gene under the control of the immunoglobulin heavy chain promoter, leading to uncontrolled cell proliferation. Less common translocations involve the light chain loci on chromosomes 2 and 22. The overexpression of MYC, a transcription factor that regulates cell growth and apoptosis, drives the rapid growth of Burkitt’s lymphoma cells.
Clinical Presentation
Patients with Burkitt’s lymphoma often present with rapidly growing tumors, which can double in size within 24 to 48 hours. Symptoms vary depending on the location of the tumors:
- Abdominal tumors: Abdominal pain, swelling, gastrointestinal bleeding, or bowel obstruction.
- Jaw or facial bone tumors: Swelling, pain, and tooth displacement (more common in endemic Burkitt’s lymphoma).
- Central nervous system involvement: Headaches, seizures, cranial nerve palsies, or altered mental status.
- Systemic symptoms: Fever, night sweats, and weight loss (B symptoms).
Diagnosis
The diagnosis of Burkitt’s lymphom. requires a combination of clinical evaluation, imaging studies, and biopsy. Diagnostic procedures typically include:
- Biopsy: A tissue sample from the affected lymph node or tumor mass is obtained for histopathological examination. Burkitt’s lymphoma is characterized by a “starry sky” appearance due to interspersed macrophages among the rapidly dividing lymphocytes.
- Immunohistochemistry: Staining for specific markers such as CD10, CD20, BCL6, and Ki-67 (a marker of proliferation) helps confirm the diagnosis.
- Genetic studies: Fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) techniques are used to detect MYC gene rearrangements, which are characteristic of Burkitt’s lymphoma.
- Imaging: CT scans, MRI, and PET scans help determine the extent of the disease and identify sites of involvement.
- Bone marrow biopsy and lumbar puncture: These are performed to assess bone marrow and central nervous system involvement.
Treatment
Burkitt’s lymphoma is a highly aggressive cancer, but it is also highly responsive to intensive chemotherapy. The choice of treatment depends on the patient’s age, overall health, and disease extent. Standard treatment options include:
- Chemotherapy: Combination chemotherapy regimens such as CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, methotrexate/ifosfamide, etoposide, and cytarabine) are commonly used. High-dose methotrexate and cytarabine are crucial components due to their ability to penetrate the central nervous system.
- Immunotherapy: Rituximab, a monoclonal antibody targeting CD20, is often added to chemotherapy regimens to improve outcomes.
- CNS prophylaxis: Because of the high risk of central nervous system involvement, patients typically receive intrathecal chemotherapy (directly into the cerebrospinal fluid) and/or high-dose systemic chemotherapy that crosses the blood-brain barrier.
- Supportive care: This includes managing side effects of chemotherapy, preventing infections, and providing nutritional support.
Prognosis
The prognosis of Burkitt’s lymphoma has improved significantly with advances in treatment. The overall survival rate for children and young adults with early-stage disease can exceed 90% with intensive chemotherapy. However, the prognosis is less favorable for older adults, patients with advanced disease, or those with immunodeficiency-associated Burkitt’s lympho. Early diagnosis and prompt treatment are crucial for improving outcomes.
Conclusion
Burkitt’s lymphoma is a rare but highly aggressive form of non-Hodgkin lymphoma that requires rapid diagnosis and treatment. Advances in chemotherapy and immunotherapy have significantly improved survival rates, particularly in children and young adults. Ongoing research aims to refine treatment protocols and develop targeted therapies to further improve outcomes and reduce treatment-related toxicity.
Read more: